Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. Additionally we are shipping CTLA4 Antibodies (455) and CTLA4 Kits (40) and many more products for this protein.
Showing 10 out of 69 products:
Mouse (Murine) CTLA4 Protein expressed in CHO Cells - ABIN2666795
Gerold, Zheng, Rainbow, Zernecke, Wicker, Kissler: The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. in Diabetes 2011
Show all 7 references for ABIN2666795
Human CTLA4 Protein expressed in CHO Cells - ABIN2666793
Mittal, Chaturvedi, Rohlfsen, Gupta, Joshi, Hegde, Bociek, Joshi: Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. in PLoS ONE 2013
Show all 7 references for ABIN2666793
Human CTLA4 Protein expressed in CHO Cells - ABIN2666967
Lindsten, Lee, Harris, Petryniak, Craighead, Reynolds, Lombard, Freeman, Nadler, Gray: Characterization of CTLA-4 structure and expression on human T cells. in Journal of immunology (Baltimore, Md. : 1950) 1993
Show all 3 references for ABIN2666967
Human CTLA4 Protein expressed in HEK-293 Cells - ABIN2487344
Ross, Robinson, Amato, McMillan, Westcott, Wolf, Robinson: Therapeutic monoclonal antibodies in human breast milk: a case study. in Melanoma research 2014
Show all 2 references for ABIN2487344
Human CTLA4 Protein expressed in Escherichia coli (E. coli) - ABIN1098772
Rudd, Taylor, Schneider: CD28 and CTLA-4 coreceptor expression and signal transduction. in Immunological reviews 2009
Show all 2 references for ABIN1098772
Cynomolgus CTLA4 Protein expressed in HEK-293 Cells - ABIN2180926
Magistrelli, Jeannin, Herbault, Benoit De Coignac, Gauchat, Bonnefoy, Delneste: A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. in European journal of immunology 1999
Data suggest enhanced clinical benefit from combining CTLA-4 antigen blockade with poxvirus-based active immunotherapy.
up-regulated expression correlates with the tolerogenic effect of syngeneic hematopoietic stem cell transplantation
Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner
CTLA-4 has a regulatory T cell-intrinsic role in limiting peripheral regulatory T cell expansion and activation, and in their capacity to control conventional T cells.
The Ctla4 SNP (e2_77A/G) does not alter diabetes susceptibility, but does control mRNA alternative splicing.
Sorafenib suppressed the expression of immunosuppressive factors in MDSCs. These data indicate that combination therapy of sorafenib and anti-CTLA-4 Ab may be effective in advanced kidney cancer patients.
The co-stimulatory molecule CTLA-4 mediates in vitro differentiation of iTreg cells.
The bullseye immunological synapse formation is mediated by CTLA4, and may negatively control T-cell activation as a suppressive synapse.
this study reports that regulatory T (Treg) cells orchestrate memory T cell quiescence by suppressing effector and proliferation programs through inhibitory receptor, cytotoxic- T-lymphocyte-associated protein-4 (CTLA-4).
Short-term blockade with anti-CTLA-4 antibody in wild-type mice is sufficient to elicit follicular helper T cell generation and germinal center development. The latter occurs in a CD28 (show CD28 Proteins)-dependent manner.
No significant association was found between +49A/G (rs231775), -318C/T (rs5742909), and +6230A/G (rs3087243) CTLA-4 gene polymorphisms and lymphoid malignancies.
Studies suggest that the cytotoxic T lymphocyte associated protein 4 (CTLA4) polymorphisms of the three alleles are not associated with genetic susceptibility to non-Hodgkin's lymphoma (NHL) risk.
Immune surveillance is an important mechanism in prevention of cancer development and inhibition of growth of tumors and metastasis. Checkpoint pathways prevent immune response through multiple methods including CTLA-4 and PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins) pathways.A variety of immune checkpoint inhibitors (PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins) and CTLA-4 inhibitors) have been studied in recurrent and metastatic head and neck cancers with encouraging efficacy
n combination with anti-PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins), the CTLA-4-expanded T cells are prevented from being functionally inhibited when they enter into the tumor microenvironment.
The CTLA-4 receptor was one of the first checkpoint inhibitors to be targeted with limited exploration and efficacy in sarcoma.The PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins) immunologic checkpoint pathway has demonstrated efficacy in many malignancies; studies are ongoing in sarcoma.
We present multiplexed RO assays for an IGF1R (show IGF1R Proteins)-EGFR (show EGFR Proteins) bispecific antibody (Bs-Ab) and a CTLA4-Ig recombinant fusion protein to demonstrate key considerations for accurate RO assessment.
PD-1 (show PDCD1 Proteins) and CTLA-4 expression during the symptomatic phase was significantly higher in the T-cells of Acute Hepatitis A patients than in those of Acute Toxic Hepatitis patients or healthy controls.
anti-CTLA-4 and anti-PD-1 (show PDCD1 Proteins) immune checkpoint blockade (ICB) monoclonal antibodies are becoming parts of the oncologists' armamentarium against melanoma and non small-cell lung cancer (NSCLC).
there are a number of both peripheral blood and tumor-based laboratory tests that have been examined as potential biomarkers to predict response to either CTLA-4 or PD-1 (show PDCD1 Proteins)/PD-L1 (show CD274 Proteins) blockade.
CTLA-4 A49G polymorphism was associated with rheumatoid arthritis (RA) risk.
Suggest a truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin as a novel approach for in vivo depletion of CD80 (show CD80 Proteins)-positive cells.
The surface expression of CTLA-4 was increased in subclinical stages of paratuberculosis infection while levels of ZAP-70 (show ZAP70 Proteins) were decreased in CD4 (show CD4 Proteins)+ T cells of both subclinical and clinical animals, indicating a change in T cell phenotype with disease state.
These results suggested that the expression level of CTLA-4 in CD4 (show CD4 Proteins)-positive T cells has a potentially immunosuppressive function in bovine leukemia infection.
Experimental infection with bovine viral diarrhea virus did not provide evidence ofTreg activation based on expression of FoxP3 (show FOXP3 Proteins) and CTLA4.
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
cytotoxic T-lymphocyte-associated protein 4 precursor
, CD152 protein
, cytotoxic T-lymphocyte protein 4
, cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM
, cytotoxic T-lymphocyte-associated protein 4
, costimulatory molecule B7 receptor
, cytotoxic T lymphocyte-associated antigen 4
, CD152 antigen
, cytotoxic T-lymphocyte-associated antigen 4
, CD152 isoform
, celiac disease 3
, cytotoxic T lymphocyte associated antigen 4 short spliced form
, cytotoxic T-lymphocyte antigen 4
, cytotoxic T-lymphocyte-associated serine esterase-4
, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
, soluble form
, transmembrane form
, cytotoxic T lymphocyte-associated protein 4
, costimulatory molecule B7 receptor CD152